Darovasertib worked in metastatic uveal melanoma. Can IDEAYA now stop the cancer from returning?
IDEAYA and Servier begin a 450-patient Phase 3 trial testing whether darovasertib plus crizotinib can prevent uveal melanoma recurrence.
Pharma & Biotech
Medical Devices & Diagnostics
Can TrilliumBiO and Oncobit make MRD monitoring standard for uveal melanoma in the U.S.?
TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.